[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100636461":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":26,"responsibleParty":43,"collaborators":19,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":19,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":19,"overallStatus":29,"whyStopped":19,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"All India Institute of Medical Sciences","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"SBRT in stage III NSCLC","EXPERIMENTAL","The study will evaluate efficacy \\& toxicity of SBRT in stage III NSCLC",[13],"Radiation: SBRT in stage III NSCLC",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"RADIATION","SBRT to primary tumor and lymph nodes in stage III NSCLC when gross disease is \\\u003C 6 cms",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Aman Sharma, MD","CONTACT","+91117018529339","amans757@gmail.com",[27],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Nci, Aiims-Jhajjar","RECRUITING","Jhajjar","Haryana","124105","India","IN",{"type":36,"coordinates":37},"Point",[38,39],76.6565,28.6063,{"lat":39,"lon":38},[42],{"name":22,"role":23,"phone":19,"phoneExt":19,"email":25},{"type":44,"investigatorFullName":45,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"PRINCIPAL_INVESTIGATOR","Aman Sharma","100636461","a-phase-ii-trial-evaluating-upfront-stereotactic-body-radiotherapy-in-stage-iii-advanced-non-small-cell-lung-cancer-100636461",false,"NCT07565987","A Phase II Trial Evaluating Upfront Stereotactic Body Radiotherapy in Stage III Advanced Non-small Cell Lung Cancer","The APRIL Trial: A Phase II Trial Evaluating Upfront Stereotactic Body Radiotherapy in Stage III Advanced Non-small Cell Lung Cancer","APRIL","Inclusion Criteria:\n\n1. Aged 18 or above and less than 75 years.\n2. Histologically proven non-small cell lung cancer.\n3. Stage T1-4, N1-3, M0 with maximum tumor size less than 6 cms and ≤ 3 stations of largest lymph node size less than 4 cms.\n4. ECOG status 0-1.\n5. Available to attend long term follow- up.\n6. Written informed consent for treatment.\n\nExclusion Criteria:\n\n1. Metastatic disease.\n2. Tumor size \\> 6cm.\n3. Involved Lymph node size greater than 4 cms \\& more than 3 station of lymph nodes involved.\n4. Patients with superior vena cava obstruction.\n5. Tumor invading\u002Fencasing the proximal bronchial tree\u002F, esophagus, pericardium.\n6. Previous radiotherapy to thorax.\n7. Small cell histology.\n8. Age\\\u003C 18 or \\> 75 years.\n9. Patients on anticoagulant therapy \\& ultra-central cavitary tumors.\n10. Poor performance status ECOG 2-3.\n11. Immunocompromised states.\n12. Viral Markers negative.\n13. Pregnant women",true,"ALL","18 Years","75 Years",{"count":59,"type":60},20,"ESTIMATED","INTERVENTIONAL",[63],"NA","The aim of the study is to test the feasibility \\& loco-regional control rate by combining high precision SBRT with chemotherapy in stage III NSCLC in tumor\u002Flymph nodes if tumors\u002Flymph node size with ≤ 6cms in size.",[66],"Non Small Cell Lung Cancer","2026-04-30",{"date":69,"type":70},"2026-05-04","ACTUAL",{"date":72,"type":70},"2023-02-01",{"date":74,"type":60},"2027-01-30",{"name":5,"class":6},1]